RAPP (Rapport Therapeutics) FCF Yield % : -20.45 (As of Apr. 06, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Rapport Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Rapport Therapeutics's Trailing 12-Month Free Cash Flow is $-67.23 Mil, and Market Cap is $328.83 Mil. Therefore, Rapport Therapeutics's FCF Yield % for today is -20.45%.

The historical rank and industry rank for Rapport Therapeutics's FCF Yield % or its related term are showing as below:

RAPP' s FCF Yield % Range Over the Past 10 Years
Min: -20.45 Med: 0 Max: 0
Current: -20.45

RAPP's FCF Yield % is ranked worse than
54.75% of 1496 companies
in the Biotechnology industry
Industry Median: -15.915 vs RAPP: -20.45

Rapport Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Rapport Therapeutics FCF Yield % Historical Data

The historical data trend for Rapport Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapport Therapeutics FCF Yield % Chart

Rapport Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

FCF Yield %

-10.36

Rapport Therapeutics Quarterly Data
	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial			-	-	-8.14	-8.84	-9.04

Competitive Comparison of Rapport Therapeutics's FCF Yield %

For the Biotechnology subindustry, Rapport Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Rapport Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Rapport Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-67.233	/	648.9292
	=	-10.36%

Rapport Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-14.672	*	4	/	648.9292
	=	-9.04%

Rapport Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Rapport Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Rapport Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapport Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapport Therapeutics Inc (NAS:RAPP) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1325 Boylston Street, Suite 401, Boston, MA, USA, 02215

Website

https://www.rapportrx.com

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.